Discover how Baysient’s T3 application enables gastroenterologists to personalize subcutaneous Infliximab therapy for smaller patients with lower weights. In this walkthrough, we explore how T3 uses patient-specific data to recommend optimized dosing intervals and therapeutic targets.

Key highlights include:

✔ Utilizing Baysient’s predictive tools to balance therapeutic efficacy and minimize side effects.

✔ Managing antibody formation risks and improving mucosal healing potential.

✔ Visualizing how changes in dosing affect therapeutic outcomes over time.

T3 empowers you to move beyond one-size-fits-all dosing by providing actionable insights for tailored treatment strategies. Watch to see how you can enhance care with precision medicine.